Trastuzumab deruxtecan: Difference between revisions

Latest revision as of 16:31, 16 February 2025

Trastuzumab Deruxtecan[edit]

Trastuzumab deruxtecan is a monoclonal antibody used in the treatment of certain types of cancer. It is a drug that combines a chemotherapy agent with a targeted therapy approach, specifically designed to target HER2-positive cancer cells.

Mechanism of Action[edit]

Trastuzumab deruxtecan is an antibody-drug conjugate (ADC) that consists of a humanized monoclonal antibody linked to a topoisomerase I inhibitor. The antibody component targets the HER2 receptor, which is overexpressed in some breast cancer and gastric cancer cells. Upon binding to the HER2 receptor, the conjugate is internalized by the cancer cell, where the cytotoxic agent is released, leading to DNA damage and cell death.

Clinical Use[edit]

Trastuzumab deruxtecan is primarily used in the treatment of HER2-positive metastatic breast cancer and has shown efficacy in patients who have previously been treated with other HER2-targeted therapies. It is also being investigated for use in other HER2-expressing cancers, such as gastric cancer and lung cancer.

Side Effects[edit]

Common side effects of trastuzumab deruxtecan include nausea, fatigue, vomiting, alopecia, and neutropenia. Serious side effects can include interstitial lung disease and cardiotoxicity. Patients receiving this treatment are closely monitored for these adverse effects.

Development and Approval[edit]

Trastuzumab deruxtecan was developed by Daiichi Sankyo in collaboration with AstraZeneca. It received accelerated approval from the U.S. Food and Drug Administration (FDA) for the treatment of HER2-positive metastatic breast cancer in patients who have received two or more prior anti-HER2-based regimens in the metastatic setting.

Related Pages[edit]

@@ Line 1: / Line 1: @@
-== Trastuzumab deruxtecan ==
+== Trastuzumab Deruxtecan ==
-'''Trastuzumab deruxtecan''' is a [[monoclonal antibody]] used in the treatment of certain types of [[cancer]]. It is a [[conjugate]] of the monoclonal antibody [[trastuzumab]] and a topoisomerase inhibitor, deruxtecan. This drug is primarily used for the treatment of [[HER2-positive]] [[breast cancer]] and [[gastric cancer]].
+[[File:Trastuzumab_deruxtecan.svg|thumb|right|Chemical structure of Trastuzumab Deruxtecan]]
+'''Trastuzumab deruxtecan''' is a [[monoclonal antibody]] used in the treatment of certain types of [[cancer]]. It is a [[drug]] that combines a [[chemotherapy]] agent with a [[targeted therapy]] approach, specifically designed to target [[HER2-positive]] cancer cells.
 === Mechanism of Action ===
-Trastuzumab deruxtecan works by targeting the [[HER2]] receptor, which is overexpressed in some cancer cells. The trastuzumab component binds to the HER2 receptor, and the deruxtecan component, a cytotoxic agent, is then internalized into the cancer cell, where it induces [[DNA damage]] and [[apoptosis]].
+Trastuzumab deruxtecan is an [[antibody-drug conjugate]] (ADC) that consists of a [[humanized monoclonal antibody]] linked to a topoisomerase I inhibitor. The antibody component targets the [[HER2 receptor]], which is overexpressed in some [[breast cancer]] and [[gastric cancer]] cells. Upon binding to the HER2 receptor, the conjugate is internalized by the cancer cell, where the cytotoxic agent is released, leading to [[DNA damage]] and cell death.
 === Clinical Use ===
-Trastuzumab deruxtecan is approved for use in patients with HER2-positive breast cancer who have received prior anti-HER2-based regimens. It is also used in the treatment of HER2-positive gastric cancer. The drug has shown efficacy in patients with metastatic disease, providing an option for those who have exhausted other treatments.
+Trastuzumab deruxtecan is primarily used in the treatment of HER2-positive [[metastatic breast cancer]] and has shown efficacy in patients who have previously been treated with other HER2-targeted therapies. It is also being investigated for use in other HER2-expressing cancers, such as [[gastric cancer]] and [[lung cancer]].
 === Side Effects ===
-Common side effects of trastuzumab deruxtecan include [[nausea]], [[fatigue]], [[vomiting]], [[alopecia]], and [[neutropenia]]. Serious side effects can include [[interstitial lung disease]] and [[pneumonitis]], which require careful monitoring and management.
+Common side effects of trastuzumab deruxtecan include [[nausea]], [[fatigue]], [[vomiting]], [[alopecia]], and [[neutropenia]]. Serious side effects can include [[interstitial lung disease]] and [[cardiotoxicity]]. Patients receiving this treatment are closely monitored for these adverse effects.
 === Development and Approval ===
-Trastuzumab deruxtecan was developed by [[Daiichi Sankyo]] and [[AstraZeneca]]. It received accelerated approval from the [[U.S. Food and Drug Administration]] (FDA) in December 2019 for the treatment of HER2-positive breast cancer. Subsequent approvals have expanded its use to other indications based on ongoing clinical trials.
+Trastuzumab deruxtecan was developed by [[Daiichi Sankyo]] in collaboration with [[AstraZeneca]]. It received accelerated approval from the [[U.S. Food and Drug Administration]] (FDA) for the treatment of HER2-positive metastatic breast cancer in patients who have received two or more prior anti-HER2-based regimens in the metastatic setting.
-=== Research ===
+== Related Pages ==
-Ongoing research is exploring the use of trastuzumab deruxtecan in other HER2-expressing cancers, including [[lung cancer]] and [[colorectal cancer]]. Clinical trials are also investigating its efficacy in combination with other therapies.
-== Related pages ==
 * [[Monoclonal antibody therapy]]
 * [[HER2/neu]]
 * [[Breast cancer treatment]]
+* [[Antibody-drug conjugate]]
-{{Reflist}}
+{{Antineoplastic agents}}
-[[File:Trastuzumab_deruxtecan.svg|thumb|Structure of trastuzumab deruxtecan]]
 [[Category:Monoclonal antibodies]]
 [[Category:Antineoplastic drugs]]
-[[Category:HER2-targeted therapy]]
+[[Category:HER2-targeted therapies]]